Summit Corporation plc
("Summit plc" or "the Company")

RESULTS OF ANNUAL GENERAL MEETING

Oxford, UK, 20 August 2009 - Summit Corporation plc (AIM: SUMM), a UK
drug discovery company, announces the results from its Annual General
Meeting that was held today.  Of the seven resolutions that that were
proposed to shareholders, all were duly passed.


Share capital reorganisation

At the AGM. shareholders approved a reorganisation of the share
capital, the effect of which is that for each issued ordinary share
of 10p currently held, shareholders will be issued with one new
Ordinary Share of 1p ("Ordinary Share") and nine deferred shares of
1p each. As there will be no change in the number of Ordinary Shares
in issue, and since the rights of the deferred Shares will be such
that they have no economic value, the market price of a new Ordinary
Share with a reduced nominal value should be the same as the market
price of an existing ordinary share prior to the reorganisation.

In addition, the Company will reorganise its authorised but unissued
share capital to the effect that each authorised but unissued
ordinary share of 10p will be subdivided into 10 new Ordinary Shares
of 1p. Following this, the unissued Ordinary Shares will have the
same nominal value as the new Ordinary Shares of 1p.

Application has been made to the London Stock Exchange for the
58,300,237 new Ordinary Shares to be admitted to trading on AIM and
it is anticipated that dealings in the new Ordinary Shares will
commence at 8.00 a.m. on Friday 21 August 2009.

                               - ENDS -

For more information, please contact:

Summit plc
Steven Lee, PhD
Richard Pye, PhD
Tel: +44 (0)1235 443951

Panmure Gordon
Andrew Burnett / Rakesh Sharma (Corporate Finance)
Ashton Clanfield (Corporate Broking)
Tel: +44 (0)207 459 3600

About Summit plc
Summit plc is a UK based drug discovery company with a major focus on
developing new therapeutics from its iminosugar drug discovery
platform.  Summit believes iminosugars are the key to gaining access
to several disease mechanisms where classical drugs have had little
success, and thus offer a major opportunity for the discovery and
development of new medicines.

Carbohydrates (sugars) play critical roles in maintaining correct
functioning of many normal processes in healthy individuals and
errors in carbohydrate recognition or modification can lead to
malfunction in cells resulting in disease.  Iminosugars have the
potential to mimic carbohydrates or to interact with processes which
manipulate carbohydrates to modify activity or to correct aberrant
function.  Additionally, the structural features of iminosugars allow
them to have, have important effects when interacting with many other
unexploited therapeutic targets.

Commercially, Summit has a track record of signing programme
agreements and currently has an out-licensed product portfolio
comprising of four drug programmes with BioMarin, Orient Europharma,
Evolva and the Lilly TB Drug Discovery Initiative.  In the future
these programmes may generate success based milestone payments and
royalties for Summit.

In addition, Summit owns Dextra Laboratories, a business unit that
operates independently to Summit, which offers specialist
carbohydrate chemistry services to third parties on a fee-for-service
or collaborative basis.

The company listed on the alternative investment market (AIM) of the
London Stock Exchange in October 2004 - symbol: SUMM.  Further
information about the company is available at www.summitplc.com.

---END OF MESSAGE---




This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement.